ABBVIE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 161.2 USD | +3.15% |
|
+1.88% | +4.05% |
Presenter SpeechGeoffrey Meacham (Analysts)With me on stage is CEO, Rob Michael, currently Pre...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
161.2
USD
Average target price
182.1
USD
Spread / Average Target
+12.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.05% | 276B | |
| +40.73% | 734B | |
| +32.83% | 591B | |
| -6.30% | 350B | |
| +15.15% | 315B | |
| +15.00% | 238B | |
| +9.78% | 206B | |
| -5.52% | 204B | |
| +6.17% | 161B | |
| -0.45% | 160B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Transcript : AbbVie Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10
